Northland Securities reaffirmed their corporate rating on shares of ValiRx Plc (LON:VAL) in a research note published on Tuesday morning.

Separately, Beaufort Securities reiterated a speculative buy rating on shares of ValiRx Plc in a research note on Wednesday, September 14th.

ValiRx Plc (LON:VAL) remained flat at GBX 7.00 on Tuesday. The company’s stock had a trading volume of 739,358 shares. ValiRx Plc has a 12-month low of GBX 5.75 and a 12-month high of GBX 29.80. The stock’s market capitalization is GBX 3.06 million. The stock has a 50-day moving average of GBX 7.46 and a 200 day moving average of GBX 8.82.

ValiRx Plc Company Profile

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Stock Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related stocks with our FREE daily email newsletter.